Table 1.

Region-based sensitivities and specificities (and 95% CIs) for DWI-MRI in Group A (DLBCL, follicular lymphoma, Hodgkin lymphoma, nMZL, MCL, peripheral T-cell lymphoma, and ALCL), and DWI-MRI, 18F-FDG-PET/CTa, CE-CT, and the combination of 18F-FDG-PET/CT and CE-CTb in Group B (MALT lymphoma, SLL/CLL)

Overall (%)Nodal (%)Extranodal (%)
Group A
 DWI-MRI sensitivity97 (93.8–100)93.8 (90.0–97.5)98.6 (95.8–100)
 DWI-MRI specificity99.8 (99.6–100)99.8 (99.6–100)99.8 (99.6–100)
Group B
 DWI-MRI sensitivity94.4 (89.2–99.7)94.9 (88.3–100)93.9 (85.7–100)
 PET/CT sensitivitya60.9 (38.6–83.2)64.1 (27.4–100)57.6 (38.8–76.3)
 CE-CT sensitivity70.7 (59.7–81.8)76.9 (63.3–90.5)63.6 (46.5–80.8)
 PET/CT+CE-CT sensitivityb81.9 (71.5–89.1)94.9 (83.1–98.6)66.7 (49.6–80.2)
 DWI-MRI specificity100 (100–100)100 (100–100)100 (100–100)
 PET/CT specificitya99.8 (99.4–100)99.8 (99.4–100)99.8 (99.3–100)
 CE-CT specificity99.1 (98.5–99.7)99 (98.3–99.8)99.1 (98.3–99.9)
 PET/CT+CE-CT specificityb98.9 (89.0–99.4)98.9 (97.4–99.5)98.8 (97.5–99.5)
  • aCT used only for anatomic and morphologic correlation.

  • bRegions rated as positive if either 18F-FDG-PET/CT or CE-CT was positive.